IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.240
-0.040 (-3.13%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Company Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences, Inc.
| Country | United States |
| Founded | 1993 |
| IPO Date | Sep 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Mary Harler |
Contact Details
Address: 325 East Middlefield Road Mountain View, California 94043 United States | |
| Phone | 650 965 7873 |
| Website | igmbio.com |
Stock Details
| Ticker Symbol | IGMS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001496323 |
| CUSIP Number | 449585108 |
| ISIN Number | US4495851085 |
| Employer ID | 77-0349194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mary Beth Harler M.D. | Chief Executive Officer and Director |
| Misbah Tahir CPA | Chief Financial Officer |
| TS Harigopal | Senior Vice President of Group Operations |
| Steven Weber | Senior Vice President, Corporate Controller and Principal Accounting Officer |
| Paul C. Graffagnino J.D. | Senior Vice President of Legal Affairs |
| Suzette Tauber | Chief Human Resources Officer |
| Dr. Angus M. Sinclair Ph.D. | Executive Vice President of Research |
| Dr. Lisa L. Decker Ph.D. | Chief Business Officer |
| Dr. Marvin S. Peterson Ph.D. | Executive Vice President of Process Development and Manufacturing |
| Dr. Elizabeth Haanes J.D., Ph.D. | Senior Vice President of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 8-K/A | [Amend] Current report |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 144 | Filing |